Advertisement

FDA Approves First-of-a-Kind Test for Cancer Gene Profiling

FDA Approves First-of-a-Kind Test for Cancer Gene Profiling

MARILYNN MARCHIONE, AP Chief Medical Writer
December 01, 2017 06:26 PM

WASHINGTON (AP) - U.S. regulators have approved a first-of-a-kind test that looks for mutations in hundreds of cancer genes at once using a single tumor sample. This gives a more complete picture of what's driving a patient's tumor and aids efforts to match treatments to those flaws.

Advertisement – Content Continues Below

The Food and Drug Administration approved Foundation Medicine's test for patients with advanced or widely spread cancers, and the Centers for Medicare and Medicaid Services proposed covering it.

The dual decisions announced late Thursday will quickly make tumor gene profiling available to far more cancer patients than the few who get it now, and lead more insurers to cover it.

It also will help more patients find and enroll in studies testing new drugs that target specific genes.


Credits

MARILYNN MARCHIONE, AP Chief Medical Writer

Copyright 2017 The Associated Press. All rights reserved.

Advertisement
Advertisement
Relay Media Amp

Nolan Staying on Swanson Ticket Despite Calls to Step Aside

Former Campaign Manager Joe Radinovich, Others Weigh in on Nolan Staffer Allegations

Duluth Facility First in Minn. to Offer Kids Residential Psychiatric Treatment

Cliffs' CEO Ready for New Leadership in Minnesota

Walker Wants Federal Disaster Declaration for NW Wisconsin

Lake Superior Circle Tour Highway Reopens after Brief Closure

Advertisement